The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

The U.S. Food and Drug Administration (USFDA) on Friday approved Merilog as biosimilar to Novolog (insulin aspart) for the ...

Doctors developed it several decades ago as a guide to insulin dosage. Clinical guidelines typically recommend against using sliding scale insulin as the sole method of insulin management.

Thanks for liking this story! We have added it to a list of your favorite stories. Minnesotans prescribed insulin won’t pay more than $35 per month for it, after the conclusion of a lawsuit ...

The Affordable Insulin Now Act, as it is known ... Unfortunately, the current drug pricing bill fails to take a holistic approach to addressing a system that drives affordability challenges ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two ...

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...